JP2011500843A - 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体 - Google Patents

活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体 Download PDF

Info

Publication number
JP2011500843A
JP2011500843A JP2010531275A JP2010531275A JP2011500843A JP 2011500843 A JP2011500843 A JP 2011500843A JP 2010531275 A JP2010531275 A JP 2010531275A JP 2010531275 A JP2010531275 A JP 2010531275A JP 2011500843 A JP2011500843 A JP 2011500843A
Authority
JP
Japan
Prior art keywords
antibody
protein
apc
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010531275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500843A5 (enExample
Inventor
ジュン スー
チャールズ エスモン
Original Assignee
オクラホマ・メディカル・リサーチ・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オクラホマ・メディカル・リサーチ・ファウンデーション filed Critical オクラホマ・メディカル・リサーチ・ファウンデーション
Publication of JP2011500843A publication Critical patent/JP2011500843A/ja
Publication of JP2011500843A5 publication Critical patent/JP2011500843A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2010531275A 2007-10-26 2008-10-24 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体 Withdrawn JP2011500843A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012236531A Division JP2013049694A (ja) 2007-10-26 2012-10-26 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
JP2014136566A Division JP6117741B2 (ja) 2007-10-26 2014-07-02 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体

Publications (2)

Publication Number Publication Date
JP2011500843A true JP2011500843A (ja) 2011-01-06
JP2011500843A5 JP2011500843A5 (enExample) 2012-12-06

Family

ID=40289112

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010531275A Withdrawn JP2011500843A (ja) 2007-10-26 2008-10-24 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
JP2012236531A Pending JP2013049694A (ja) 2007-10-26 2012-10-26 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
JP2014136566A Active JP6117741B2 (ja) 2007-10-26 2014-07-02 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012236531A Pending JP2013049694A (ja) 2007-10-26 2012-10-26 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
JP2014136566A Active JP6117741B2 (ja) 2007-10-26 2014-07-02 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体

Country Status (13)

Country Link
US (3) US8153766B2 (enExample)
EP (1) EP2205638B1 (enExample)
JP (3) JP2011500843A (enExample)
KR (2) KR101856210B1 (enExample)
CN (3) CN103232541A (enExample)
AU (1) AU2008316661B2 (enExample)
BR (1) BRPI0818865A2 (enExample)
CA (1) CA2703738C (enExample)
IL (2) IL205284A (enExample)
MX (1) MX2010004615A (enExample)
RU (2) RU2539729C2 (enExample)
WO (1) WO2009055669A2 (enExample)
ZA (1) ZA201105704B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015041310A1 (ja) 2013-09-20 2015-03-26 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
JP2016501230A (ja) * 2012-11-29 2016-01-18 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体
JP2016501875A (ja) * 2012-11-29 2016-01-21 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 活性化プロテインｃに対するヒト化モノクローナル抗体およびその使用
JP2023553798A (ja) * 2021-07-13 2023-12-26 オクラホマ メディカル リサーチ ファウンデーション ヒト活性化プロテインｃを対象とするモノクローナル抗体とその製造及び応用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ730271A (en) * 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CA3067584A1 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
TW201906868A (zh) * 2017-07-07 2019-02-16 日商第一三共股份有限公司 抗蛋白ｃ抗體
EP3655437A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Human antibodies binding to ror2
EP3971573A1 (en) * 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
US12319744B2 (en) 2018-09-06 2025-06-03 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
AU2019360758B2 (en) * 2018-10-18 2024-08-08 Oklahoma Medical Research Foundation Biomarkers for a Systemic Lupus Erythematosus (SLE) disease activity immune index that characterizes disease activity
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (en) * 1991-06-24 1993-01-07 The Scripps Research Institute Apc polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibitng apc, and therapeutic methods
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (en) * 1991-06-24 1993-01-07 The Scripps Research Institute Apc polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibitng apc, and therapeutic methods
WO2002029015A1 (en) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013039728; Ｊｏｕｒｎａｌ　ｏｆ　ｐｒｏｔｅｉｎ　ｃｈｅｍｉｓｔｒｙ．　１９９９，　Ｖｏｌ．１８，　Ｎｏ．７，　ｐ．７７９-７８４ *
JPN6013039731; Ｂｌｏｏｄ．　２００４，　Ｖｏｌ．１０４，　Ｎｏ．６，　ｐ．１７４０-１７４４ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501230A (ja) * 2012-11-29 2016-01-18 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体
JP2016501875A (ja) * 2012-11-29 2016-01-21 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 活性化プロテインｃに対するヒト化モノクローナル抗体およびその使用
WO2015041310A1 (ja) 2013-09-20 2015-03-26 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
JPWO2015041310A1 (ja) * 2013-09-20 2017-03-02 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
JP2023553798A (ja) * 2021-07-13 2023-12-26 オクラホマ メディカル リサーチ ファウンデーション ヒト活性化プロテインｃを対象とするモノクローナル抗体とその製造及び応用
JP7670823B2 (ja) 2021-07-13 2025-04-30 オクラホマ メディカル リサーチ ファウンデーション ヒト活性化プロテインｃを対象とするモノクローナル抗体とその製造及び応用

Also Published As

Publication number Publication date
JP2014237651A (ja) 2014-12-18
CN103232541A (zh) 2013-08-07
US20120164150A1 (en) 2012-06-28
IL220622A0 (en) 2012-08-30
MX2010004615A (es) 2010-07-06
US20090110683A1 (en) 2009-04-30
RU2012150953A (ru) 2014-06-10
EP2205638B1 (en) 2017-03-01
AU2008316661B2 (en) 2013-05-23
CN101918453A (zh) 2010-12-15
RU2539729C2 (ru) 2015-01-27
IL205284A (en) 2014-06-30
WO2009055669A2 (en) 2009-04-30
EP2205638A2 (en) 2010-07-14
US8153766B2 (en) 2012-04-10
JP6117741B2 (ja) 2017-04-19
KR20150092358A (ko) 2015-08-12
KR101856210B1 (ko) 2018-05-09
JP2013049694A (ja) 2013-03-14
AU2008316661A1 (en) 2009-04-30
RU2010121148A (ru) 2011-12-10
BRPI0818865A2 (pt) 2015-05-05
IL205284A0 (en) 2010-12-30
CN105153308A (zh) 2015-12-16
US20150344588A1 (en) 2015-12-03
US9127072B2 (en) 2015-09-08
CA2703738A1 (en) 2009-04-30
CA2703738C (en) 2018-02-27
KR20100116166A (ko) 2010-10-29
ZA201105704B (en) 2014-05-28
WO2009055669A3 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
JP6117741B2 (ja) 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
JP7350821B2 (ja) 様々な疾患および障害の治療のためのｍａｓｐ－３を阻害する組成物および方法
JP6771531B2 (ja) 様々な疾患および障害の治療のためにｍａｓｐ−１および／またはｍａｓｐ−２および／またはｍａｓｐ−３を阻害する組成物および方法
AU2014301041A1 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
AU2016203760B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2015200348B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2013202464B2 (en) Monoclonal antibodies against activated and unactivated protein c
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c
EP4085252A1 (en) Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140805

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140912

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150324

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20151209